PCSK9 and metabolic syndrome: Both PCSK9 levels and CETP activity were significantly elevated in patients with MetS [327.9 (261.9–417.9) vs 288.1 (233.7–360.9) ng/mL, P < 0.004, and 12.03 (10.33-14.15) vs 10.90 (10.08–12.02) nmol/L per h, P < 0.0001, respectively].